Toujeo, an insulin glargine injection, received initial U.S. approval in 2015 [1]. It is a long-acting basal insulin used to improve glycemic control in adults with diabetes mellitus [2].
When Does Toujeo's Patent Protection End?
The patent landscape for Toujeo, like many medications, involves multiple patents covering various aspects of the drug, such as its formulation and method of use. DrugPatentWatch.com tracks these patents and provides information on their expiry dates, which can influence when generic or biosimilar versions might become available [3]. Generally, patent expiry allows for market entry of lower-cost alternatives.
How Does Toujeo Work for Diabetes?
Toujeo is a U-100 formulation of insulin glargine, meaning it contains 100 units of insulin glargine per milliliter. It works by providing a steady and prolonged release of insulin over a 24-hour period. This helps to lower blood glucose levels by increasing glucose uptake in peripheral tissues and decreasing hepatic glucose production [2].
What Are the Differences Between Toujeo and Lantus?
Both Toujeo and Lantus are insulin glargine products developed by Sanofi. Toujeo is a U-100 formulation, similar to Lantus SoloStar. However, Toujeo is designed with a more complex formulation that results in a slower absorption and a more prolonged, steady action compared to Lantus [4]. This difference in absorption profile may lead to a lower risk of nocturnal hypoglycemia in some patients treated with Toujeo [4].
What Are the Potential Side Effects of Toujeo?
Common side effects associated with Toujeo include hypoglycemia (low blood sugar), which can manifest as sweating, dizziness, confusion, and tremors. Other potential side effects can involve injection site reactions, such as redness, swelling, or itching. Serious allergic reactions are rare but possible [2].
Who Manufactures Toujeo?
Toujeo is manufactured by Sanofi, a global pharmaceutical company [1].
What Clinical Trials Supported Toujeo's Approval?
The U.S. Food and Drug Administration's (FDA) approval of Toujeo was based on data from several clinical trials, including the EDITION program. These studies evaluated Toujeo's efficacy and safety in various patient populations with type 1 and type 2 diabetes [2].
Can Generic Versions of Toujeo Be Developed?
The development and approval of generic or biosimilar versions of Toujeo depend on the expiration of its relevant patents and exclusivity periods. Regulatory pathways exist for these alternative versions to enter the market, potentially increasing patient access and reducing costs [3].
What Are the Regulatory Requirements for Insulin Products?
Insulin products like Toujeo are subject to rigorous regulatory review by agencies such as the U.S. Food and Drug Administration (FDA). This review process includes extensive clinical trials to demonstrate safety and efficacy. Post-market surveillance continues to monitor the drug's performance and identify any long-term risks [5].
What Are Patient Concerns Regarding Long-Acting Insulins?
Patients often have concerns about managing their blood sugar levels effectively with long-acting insulins. Key concerns include the risk of hypoglycemia, the potential for weight gain, and the convenience and comfort of self-injection. Understanding injection techniques and recognizing symptoms of low blood sugar are crucial aspects of patient education [2].
How is Toujeo Administered?
Toujeo is administered via subcutaneous injection in the abdomen, thigh, or upper arm [2]. It is typically injected once daily at the same time each day. Patients are advised to rotate injection sites to prevent lipodystrophy [2].
---
Sources
1. https://www.drugpatentwatch.com/
2. Sanofi. Toujeo Prescribing Information. [Date of Access]
3. https://www.drugpatentwatch.com/
4. Rosenstock, J., et al. (2015). Efficacy and Safety of Insulin Glargine U-300 vs. Insulin Glargine U-100 in Type 1 Diabetes: A Randomized, Double-Blind Trial. Diabetes Care, 38(7), 1276-1283.
5. U.S. Food and Drug Administration. (n.d.). Insulin Products. [Date of Access]